EP1959927A1 - Zusammensetzung in form eines sprays mit einer kortikoid- und einer ölphase - Google Patents

Zusammensetzung in form eines sprays mit einer kortikoid- und einer ölphase

Info

Publication number
EP1959927A1
EP1959927A1 EP06842070A EP06842070A EP1959927A1 EP 1959927 A1 EP1959927 A1 EP 1959927A1 EP 06842070 A EP06842070 A EP 06842070A EP 06842070 A EP06842070 A EP 06842070A EP 1959927 A1 EP1959927 A1 EP 1959927A1
Authority
EP
European Patent Office
Prior art keywords
composition according
composition
disorders
oils
oily phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06842070A
Other languages
English (en)
French (fr)
Inventor
Nathalie Willcox
Sandrine Orsoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of EP1959927A1 publication Critical patent/EP1959927A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the invention relates to an anhydrous composition in the form of a spray comprising, as a pharmaceutical active agent, a corticosteroid, preferentially clobetasol propionate and an oily phase in a physiologically acceptable medium, its preparation process, and its use in dermatology.
  • compositions which, not only must be physically and chemically stable, but must also make it possible to release the active ingredient and to promote its penetration into the skin. through the skin layers to improve its effectiveness.
  • compositions must, in addition, have good cosmetics and be preferably non-irritating.
  • compositions comprising an active agent of corticoid type and to promote its penetration into the skin through the presence in particular of a high content of glycol penetrant.
  • These compositions are formulated in the form of emulsions with a high fat content, which are commonly known as “lipocremes”, in the form of anhydrous compositions known as “ointments”, in the form of fluid compositions with a high content of volatile solvents. , such as ethanol or isopropanol, intended for applications on the scalp, also called “hair lotions”, or in the form of viscous O / W emulsions, also called “O / W creams. ".
  • compositions often contain a high percentage of petrolatum to promote occlusivity and penetration of the active ingredient, but therefore have the disadvantage of being very greasy and sticky, thus not favoring the comfort and ease of application.
  • Other types of compositions commonly encountered in the prior art contain a high percentage of propenetrating glycol to promote the penetration of the active but are sticky and can cause intolerance problems.
  • No. 6,579,512 describe sprayable compositions comprising a high percentage of alcoholic and / or volatile solvents, and not of oily type. Although easier to apply, these compositions can not provide the desired emollient effect for the comfort of patients.
  • composition containing clobetasol propionate is meant any composition comprising exclusively as active ingredient clobetasol propionate.
  • the composition does not contain a vitamin D derivative, and in particular no calcitriol.
  • physical stability is meant a composition having no macroscopic appearance modification (phase separation, change of appearance color, etc.) or microscopic (recrystallization of the active) after storage at temperatures of 25 ° C, 4 ° C and 40 ° C, for 2, 4, 8, 12 weeks.
  • chemical stability is meant a composition in which the content of active ingredient remains stable after three months at room temperature and at 40 ° C.
  • a stable content of active ingredient means according to the invention that the content has very little variation with respect to the initial content, that is to say that the variation of active principle content at time T must not be less than 90% and more particularly at 95% of the initial content at TO.
  • a liquid composition at room temperature comprising, in a pharmaceutically acceptable vehicle: a) a therapeutically effective amount of a corticoid in solubilized form and more particularly clobetasol propionate; (b) an oily phase composed of one or more oils; said composition not comprising a vitamin D derivative, led to a composition which solves the problems posed.
  • the corticosteroid is selected from the group consisting of betamethasone, clobetasol, clobetasone, deoximethasone, diflucortolon, diflorasone, fluocinonide, flumethasone, fluocinolon, fluticasone, fluprednidene, halcinonide, hydrocortisone, momethasone, triamcinolon and their pharmaceutically acceptable esters and acetonides and mixtures thereof.
  • the composition according to the invention mainly comprises, as active principle, a corticosteroid, preferably clobetasol propionate.
  • liquid at room temperature a composition having a viscosity of between 3 and 30 Pa ⁇ s (3000 and 30000 centipoise), viscosity measured with a Brookfield model LVDV II + mobile # 4, at a rate of 30 rpm for 30 seconds and at a temperature of 25 ° C +/- 3 ° C.
  • composition of the present invention is chemically and physically stable while allowing good penetration of the active ingredients. It also has a very good acceptability and tolerance to patients, by its spray formula, as described in the examples of the present invention. It turns out that the composition according to the invention is particularly suitable for the treatment of dermatological conditions and more particularly well suited for the treatment of psoriasis.
  • the invention therefore relates to a liquid composition at room temperature, preferably sprayable, comprising, in a pharmaceutically acceptable vehicle: a) a therapeutically effective amount of clobetasol propionate in solubilized form; b) an oily phase composed of one or more oils, said composition not comprising a vitamin D derivative, in particular not comprising calcitriol.
  • composition according to the invention contains exclusively as active ingredient clobetasol propionate.
  • solubilized form is meant a dispersion of the active agent in the molecular state in a liquid, no crystallization of the active agent being visible to the naked eye or even to the optical microscope in cross polarization.
  • sprayable composition is meant a liquid composition, fluid and flowing quickly under its own weight, at room temperature.
  • ambient temperature is meant a temperature of about 25 ° C.
  • the spray can be obtained by conventional means of formulation known to those skilled in the art, as explained below.
  • the composition is anhydrous.
  • anhydrous composition is meant in the sense of the present invention, a composition substantially free of water, that is to say having a water content less than or equal to 5% by weight relative to the total weight of the composition, in particular less than or equal to 1%, preferably zero.
  • the composition according to the invention comprises between 0.0001 and 0.1% by weight relative to the total weight of the composition of a corticoid, preferably between 0.001 and 0.05% by weight.
  • the preferred compositions according to the invention more particularly comprise 0.01%, 0.025% or 0.05% of clobetasol propionate by weight relative to the total weight of the composition.
  • oily phase is meant an oily phase suitable for a pharmaceutical composition.
  • the oily form is ideal for psoriasis pathology and close to a cosmetic massage oil.
  • This oily liquid form makes it possible to provide the patient with an emollient comfort without the disadvantages of applying a thick, very tacky and greasy ointment.
  • the choice and the ratio of the mixture of oils are made according to their spreading powers, their chemical qualities and their solvent power of the active principle.
  • the choice of oils used according to the invention will be such that their mixture is clear and stable over time.
  • the majority oil of the oily phase according to the present invention inter alia acts as solubilizer of the active (also called active solvent).
  • the active ingredient is completely solubilized in the majority oil.
  • Oils are the only active solvent solvents that can be used according to the present invention. Thus, alcohol and glycol solvents are particularly excluded from the present invention.
  • majority oil according to the invention is meant an oil present at a percentage greater than or equal to 50% by weight relative to the total weight of the oily phase of the composition.
  • the amount of the following oil to be included in the composition will be defined by the amount of active ingredient to be solubilized.
  • the solubility of the active ingredient has been tested in various oils that can be used in the composition according to the invention.
  • the oily phase of the composition according to the invention may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, and mixtures thereof.
  • paraffin oils of different viscosities such as Primol 352, Marcol 82, Marcol 152 sold by Esso.
  • sweet almond oil there may be mentioned sweet almond oil, palm oil, soybean oil, sesame oil, sunflower oil.
  • octyldodecanol an ester such as cetearyl isononanoate such as the product sold under the name Cetiol SN by Cognis France, diisopropyl adipate as the product sold under the name Ceraphyl 230 by the company ISF, isopropyl palmitate, such as the product sold under the name Crodamol IPP by Croda, isononyl isononanoate such as Dub Inin from Stréarinerie Dubois, caprylic caprylic triglyceride such as Miglyol 812 sold by HuIs / Lambert Rivière, dioctyl ether such as Cetiol OE sold by COGNIS France, PPG-15 stearyl ether such as Arlamol E sold by Uniqema; ethyl oleate such as
  • silicone oil mention may be made of a dimethicone such as the product sold under the name Dow Corning 200 fluid or Q7 9120 from Dow Corning, a cyclomethicone such as the product sold under the name Dow Corning 244 fluid by Dow Corning or the product sold under the name Mirasil CM5 by SACI-CFPA. It is also possible to mention volatile silicone oils such as linear siloxanes and more preferentially hexamethyldisiloxane. By way of example, mention may be made of the product marketed by Dow Corning, DC Fluid 0.65cSt.
  • the compounds constituting the oily phase of the composition according to the invention are caprylic / capric triglycerides, sold under the name Miglyol 812, cetearyl isononanoate marketed under the name Cetiol SN, cyclomethicones such as cyclomethicone 5 sold under the name Mirasil CM5, dimethicones such as dimethicone 200 of 20cst viscosity, sweet almond oil, ethyl oleate, dioctyl ether and PPG-15 stearyl ether, used alone or as a mixture.
  • Miglyol 812 cetearyl isononanoate
  • Cetiol SN cetearyl isononanoate
  • cyclomethicones such as cyclomethicone 5 sold under the name Mirasil CM5
  • dimethicones such as dimethicone 200 of 20cst viscosity, sweet almond oil, ethyl
  • Triglycerides are a component of the skin, they are part of the natural lipids of the skin with ceramides, cholesterol, phospholipids. They integrate in the deep layers of the epidermis and compensate for the loss of hydration of the skin. The protective barrier of the skin is regenerated in a specific and lasting way.
  • the "Medium triglyceride chain" of which Miglyol 812 is a member is composed of caprylic (C8) and capric (C10) fatty acids derived from coconut oil or palm kernel oil.
  • Cetaryl isononanoate is an ester which has the particularity of presenting a dry and soft touch on the skin.
  • Cyclomethicone 5 is a volatile silicone oil that allows easy application to the skin and leaves a relatively dry feeling after application. - Choice of dimethicone 200 of viscosity 20cst
  • Dimethicone is a silicone oil that allows easy application to the skin, avoids the soapiness of the fat and leaves a feeling of non-greasy touch after application.
  • Sweet almond oil is a vegetable oil used for its softening properties.
  • This also allows the patient to apply the product in spray form and allows a possible massage of the area to be treated, unlike a highly volatile sprayed product.
  • composition according to the invention comprises between 50 and 99% by weight relative to the total weight of the oily phase, preferably between 70 and 99% by weight, and more preferably between 85% and 99% by weight.
  • the invention therefore relates to a sprayable composition
  • a sprayable composition comprising, in a pharmaceutically acceptable vehicle: a) between 0.0001 and 0.1% of clobetasol propionate; b) between 50 and 99.9999% of an oily phase composed of one or more oils, selected from caprylic / capric triglycerides, cetearyl isononanoate, ethyl oleate, PPG-15 stearyl ether, dioctyl ether , cyclomethicones, dimethicones, sweet almond oil, said composition not comprising a vitamin D derivative.
  • the preferred sprayable composition according to the present invention comprises, in a pharmaceutically acceptable carrier: a) between 0.001 and 0.05% clobetasol propionate; b) between 85% and 99.999% of an oily phase composed of one or more oils, selected from caprylic / capric triglycerides, cetearyl isononanoate, ethyl oleate, PPG-15 stearyl ether, dioctyl ether and cyclomethicones, dimethicones, sweet almond oil, said composition not comprising a vitamin D derivative.
  • oils selected from caprylic / capric triglycerides, cetearyl isononanoate, ethyl oleate, PPG-15 stearyl ether, dioctyl ether and cyclomethicones, dimethicones, sweet almond oil, said composition not comprising a vitamin D derivative.
  • composition according to the invention may also contain surfactants.
  • the surfactants that can be used according to the invention are of the anionic surfactant type, such as the carboxylates, and especially the soaps, the alkyl aryl sulphonates, the alkyl ether sulphates, the alkyl sulphates and the alcohol sulphates. More particularly, the anions of these surfactants are coupled to a cation such as sodium or potassium metal cations.
  • the preferred surfactants according to the invention are also the surfactants of polysorbate and poloxamer type.
  • the surfactants used according to the present invention are sodium lauryl sulfate, polysorbate 80 (TWEEN 80 from Uniqema) and poloxamer 124 (SYNPERONIC PEL44 from Uniqema)
  • the composition according to the invention also comprises propenetrating agents.
  • the propenetrating agents that can be used according to the invention are of the alcohol type such as ethanol, or of the glycol type, such as 1, 2 propanediol, known under the name of propylene glycol sold by Dow Chemical, or of dimethyl isosorbide type such as Arlasolve.
  • DMI sold by Uniqema
  • the ethoxydiglycol sold under the name of Transcutol HP by Gattefossé
  • the oleyl alcohol sold under the name of HD Eutanol V PH by Cognis
  • the n-methyl 2 pyrrolidone sold under the name of Pharmasolve by ISP and their mixtures.
  • the propenetrating agent is advantageously chosen from fatty acids and their esters, such as in particular myristyl lactate, PEG8 caprylic / capric glycerides sold under the name Labrasol by Gattefossé, oleic acid sold under the name Olein V2 by Stearinerie Dubois, propylene glycol monolaurate sold under the name Lauroglycol FCC by Gattefossé, and mixtures thereof.
  • the propenetrants used are different from propylene glycol. Indeed, the presence of these propenetrants makes it possible to formulate the corticoid in anhydrous propenetrating formulas without using propylene glycol.
  • the propenetrants are chosen from myristyl lactate, dimethyl isosorbide, n-methyl 2 pyrrolidone, PEG8 caprilic / capric glycerides and oleic acid. Even more preferentially, the propenetrant is myristyl lactate.
  • at least one oil of the composition is cetearyl isononanoate.
  • composition according to the invention may also contain inert additives or combinations of these additives, such as:
  • pH regulating agents osmotic pressure modifying agents
  • UV-A and UV-B filters are UV-A and UV-B filters
  • the composition according to the invention is more particularly intended for the treatment of skin and mucous membranes and is sprayable and suitable for conditioning in the form of a spray.
  • the spray has many advantages over conventional forms such as the ease of delivering the formula in very difficult areas of the body to be treated, the ability to easily control the dose delivered or the absence of contamination during use.
  • the composition according to the invention is thus administered in the form of a sprayable composition. This can be obtained by conventional means of formulation known to those skilled in the art.
  • the composition may be sprayed by a mechanical sprayer that pumps the composition into a container, vial or the like.
  • the composition can be propelled by means of a gas as is well known to those skilled in the art.
  • the composition passes through a nozzle that can be directed directly to the desired location of the application.
  • the nozzle may be chosen so as to apply the composition in the form of a vaporization or a jet of droplet, according to the techniques known to those skilled in the art.
  • the spray mechanism must be able to always deliver the same amount of active ingredient.
  • Mechanisms for controlling the amount of composition to be delivered by the spray are also known to those skilled in the art.
  • the amount of propellant can be calculated to propel the exact amount of product desired.
  • the composition according to the invention it is possible to use a metering spray bottle whose surface characteristics of application and doses are controlled and reproducible.
  • the vaporizer may be constituted by a bottle equipped with a metering valve.
  • composition of the present invention is chemically and physically stable while allowing good penetration of the active ingredient. It also has a very good acceptability and tolerance to patients, by its spray formula, as described in the examples of the present invention. It is therefore found that the composition according to the invention is particularly suitable for the treatment of dermatological conditions.
  • composition according to the invention for the manufacture of a medicinal product intended for treatment:
  • dermatological disorders related to a disorder of keratinization relating to differentiation and proliferation in particular vulgar, comedonal, polymorphic, rosacea acne, nodulocystic acne, conglobata, senile acnes, secondary acne such as solar acne, drug or professional,
  • ichthyosis ichthyosiform states
  • Darrier's disease palmoplantar keratoderma
  • leukoplakia and leukoplasiform states cutaneous or mucosal lichen (oral)
  • dermatological conditions with an inflammatory immunoallergic component with or without a cell proliferation disorder, in particular cutaneous, mucous or ungual psoriasis, psoriatic arthritis, cutaneous atopy, such as eczema, respiratory atopy or gingival hypertrophy, - benign or malignant dermal or epidermal proliferations, of viral or non-viral origin, in particular common warts, flat warts, verruciform epidermodysplasia, oral or florid papillomatoses, T-cell lymphoma,
  • pigmentation such as hyperpigmentation, melasma, hypopigmentation or vitiligo
  • lipid metabolism diseases of lipid metabolism, such as obesity, hyperlipidemia, noninsulin-dependent diabetes or syndrome X,
  • alopecia of various origins in particular alopecia due to chemotherapy or radiation, disorders of the immune system, such as asthma, type I diabetes mellitus, multiple sclerosis, or other selective malfunctions of the body. immune system, or
  • composition in a preferred mode of use of the composition, it will contain 0.01%, 0.025% or 0.05% of clobetasol 17-propionate and will be used for the manufacture of a medicament for treating psoriasis.
  • compositions according to the present invention are manufactured at room temperature, under fume hood and inactinic light.
  • the maximum solubility of clobetasol propionate has been studied in the following different oils according to the invention, in order to allow the choice most suited to the concentration of active agent to be solubilized. It is measured by the UV dosing method.
  • Saturated solutions are prepared according to the following procedure: 0.1% of clobetasol propionate is added to the oily excipient. the whole is stirred for 1 night and then left without stirring for two hours. Then the solutions for the UV assay are prepared by taking the supernatant. 0.1 g of this saturated solution is weighed into a volumetric flask of 100 ml and then added to 100 ml with absolute ethanol. The determination makes it possible to obtain a maximum solubility data of the active agent in the following oil considered.
  • Solubility can also be assessed visually. Thus, minute proportions of the active are gradually added with stirring to the solvent oil. A visual observation of the clarity of the solution is made. The appearance of a disorder means that the maximum percentage of asset to be incorporated has been reached from which deduction of a maximum solubility value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP06842070A 2005-11-30 2006-11-30 Zusammensetzung in form eines sprays mit einer kortikoid- und einer ölphase Withdrawn EP1959927A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512176A FR2893845B1 (fr) 2005-11-30 2005-11-30 Composition sous forme de spray comprenant un corticoide et une phase huileuse
PCT/FR2006/051259 WO2007063254A1 (fr) 2005-11-30 2006-11-30 Composition sous forme de spray comprenant un corticoide et une phase huileuse

Publications (1)

Publication Number Publication Date
EP1959927A1 true EP1959927A1 (de) 2008-08-27

Family

ID=36716957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06842070A Withdrawn EP1959927A1 (de) 2005-11-30 2006-11-30 Zusammensetzung in form eines sprays mit einer kortikoid- und einer ölphase

Country Status (5)

Country Link
US (2) US20080300229A1 (de)
EP (1) EP1959927A1 (de)
CA (1) CA2631123C (de)
FR (1) FR2893845B1 (de)
WO (1) WO2007063254A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
EP2526930B1 (de) 2005-06-01 2013-12-25 GlaxoSmithKline Intellectual Property Development Limited Vitaminformulierung
CA2615173C (en) 2005-07-14 2012-01-03 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
JP2010506941A (ja) * 2006-10-17 2010-03-04 リセラ，インク． 甲状腺眼症の治療のための方法、組成物及び製剤
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
JP5833007B2 (ja) 2009-08-31 2015-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ステロイドを含む局所製剤
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
CA2801623A1 (en) * 2010-06-25 2011-12-29 G. Pohl-Boskamp Gmbh & Co. Kg Agent for the treatment of skin conditions
WO2012071480A2 (en) * 2010-11-24 2012-05-31 Lithera, Inc. Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
AU2012251135A1 (en) * 2011-05-02 2013-11-07 Lipidor Ab Treatment of psoriasis
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201616088D0 (en) * 2016-09-21 2016-11-02 Avexxin As Pharmaceutical composition
CN109789111B (zh) 2016-09-21 2021-11-16 埃维克辛公司 药物组合物
US20190008969A1 (en) * 2017-07-06 2019-01-10 Tioga Research, Inc. Compositions for drug delivery
WO2019224035A1 (en) 2018-05-24 2019-11-28 Almirall, S.A. Topical pharmaceutical compositions comprising a corticosteroid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343798A (en) * 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US5972920A (en) * 1998-02-12 1999-10-26 Dermalogix Partners, Inc. Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
US6656928B1 (en) * 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6579512B2 (en) * 2001-06-15 2003-06-17 Crutchfield, Iii Charles E. Topical steroid spray
ES2532906T5 (es) * 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
FR2856301B1 (fr) * 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
DE602004012440T2 (de) * 2003-11-21 2009-03-26 Galderma Research & Development Sprühbare zusammensetzung zur verabreichung von vitamin d derivaten
FR2871698B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse
AU2005279704B2 (en) * 2004-08-31 2010-05-13 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007063254A1 *

Also Published As

Publication number Publication date
FR2893845A1 (fr) 2007-06-01
CA2631123A1 (fr) 2007-06-07
US20080300229A1 (en) 2008-12-04
FR2893845B1 (fr) 2010-10-29
CA2631123C (fr) 2014-01-21
WO2007063254A1 (fr) 2007-06-07
US20110152228A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
EP1641463B1 (de) Zusammensetzungen in form eines sprays mit einem pharmazeutischen mittel, mindestens einem flüchtigen silikon und einer nichtflüchtigen öligen phase
FR2871698A1 (fr) Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse
EP1765356B1 (de) Sprayzusammensetzung mit einer kombination aus calcitriol und clobetasolpropionat, einer alkoholischen phase, mindestens einer flüchtigen silikonphase und einer nichtflüchtigen öligen phase
CA2631123C (fr) Composition sous forme de spray comprenant un corticoide et une phase huileuse
EP2419082B1 (de) Topische pharmazeutische zusammensetzung mit einem wasserempfindlichen wirkstoff
CA2617963A1 (fr) Emulsion de type huile-dans-eau pour application topique en dermatologie
CA2670601A1 (fr) Compositions sous forme d'onguent comprenant un derive de vitamine d
FR2862540A1 (fr) Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US20080293681A1 (en) Sprayable pharmaceutical compositions comprising a vitamin d derivative and an oily phase
FR2871700A1 (fr) Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, et une phase huileuse
JP2008502645A (ja) 油性相中にコルチコイドとビタミンｄ誘導体との組み合わせを含むスプレー形態の組成物
CA2567680A1 (fr) Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises.
EP2872116B1 (de) Dermatologische zusammensetzung mit oleosomen und retinoiden, verfahren zur herstellung davon und verwendung davon
JP2008502646A (ja) プロピオン酸クロベタゾールとカルシトリオールとの組合せ、アルコール相、および油性相を含むスプレーの形態の組成物
EP3302421B1 (de) Zusammensetzungen mit mindestens einem dispergierten wirkstoff und lipid-mikrokapseln
FR2894474A1 (fr) Gel depigmentant hydroalcoolique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080630

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20081029

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20151029